NCT02756130 2025-05-13
Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)
Jonsson Comprehensive Cancer Center
Phase 1/2 Withdrawn
Clinical Trials
9 trialsNCT04553692 2025-03-28
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
Phase 1 Terminated
NCT01573780 2022-08-15
Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors
Roswell Park Cancer Institute
Phase 1 Terminated
NCT02587962 2021-01-14
Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors
Medivir
Phase 1/2 Terminated
NCT01681368 2017-05-30
Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02147873 2016-10-20
Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
TetraLogic Pharmaceuticals
Phase 2 Terminated
NCT01188499 2016-05-30
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
TetraLogic Pharmaceuticals
Phase 1/2 Completed
NCT00993239 2016-03-03
Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma
TetraLogic Pharmaceuticals
Phase 1 Completed
NCT01940172 2016-01-14
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
TetraLogic Pharmaceuticals
Phase 1 Completed